TY - JOUR
TI - Genotyping KRAS and EGFR mutations in Greek patients with non-small-cell lung cancer: Incidence, significance and implications for treatment
AU - Linardou, H.
AU - Kotoula, V.
AU - Kouvatseas, G.
AU - Mountzios, G.
AU - Karavasilis, V.
AU - Samantas, E.
AU - Kalogera-Fountzila, A.
AU - Televantou, D.
AU - Papadopoulou, K.
AU - Mavropoulou, X.
AU - Daskalaki, E.
AU - Zaramboukas, T.
AU - Efstratiou, I.
AU - Lampaki, S.
AU - Rallis, G.
AU - Res, E.
AU - Syrigos, K.N.
AU - Kosmidis, P.A.
AU - Pectasides, D.
AU - Fountzilas, G.
JO - Cancer Genomics and Proteomics
PY - 2019
VL - 16
TODO - 6
SP - 531-541
PB - International Institute of Anticancer Research
SN - null
TODO - 10.21873/CGP.20154
TODO - epidermal growth factor receptor;  K ras protein;  EGFR protein, human;  epidermal growth factor receptor;  KRAS protein, human;  protein p21, adult;  aged;  Article;  cancer incidence;  cancer therapy;  controlled study;  current smoker;  female;  follow up;  gene mutation;  genotype;  Greece;  human;  human tissue;  lung adenocarcinoma;  major clinical study;  male;  non small cell lung cancer;  overall survival;  retrospective study;  clinical trial;  disease free survival;  genetics;  genotyping technique;  lung tumor;  middle aged;  mortality;  mutation;  non small cell lung cancer;  survival rate;  very elderly, Adult;  Aged;  Aged, 80 and over;  Carcinoma, Non-Small-Cell Lung;  Disease-Free Survival;  ErbB Receptors;  Female;  Follow-Up Studies;  Genotyping Techniques;  Humans;  Lung Neoplasms;  Male;  Middle Aged;  Mutation;  Proto-Oncogene Proteins p21(ras);  Retrospective Studies;  Survival Rate
TODO - Background/Aim: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC) and their prognostic role is unclear. We studied KRAS and EGFR genotyping in Greek NSCLC patients. Patients and Methods: KRAS and EGFR genotypes were centrally evaluated in 421 NSCLC patients (diagnosed September 1998 -June 2013) and associated with clinicopathological parameters. Outcome comparisons were performed in 288 patients receiving first line treatment. Results: Most patients were male (78.6%), >60 years old (63.9%), current smokers (51.1%), with adenocarcinoma histology (63.9%). EGFR and KRAS mutations were found in 10.7% and 16.6% of all histologies, respectively, and in 14.9% and 21.9% of adenocarcinomas. At 4.5 years median follow-up, KRAS status was an independent negative prognostic factor for overall survival (OS, p=0.016). KRAS mutations conferred 80% increased risk of death in patients receiving first-line treatment (p=0.002). Conclusion: The presence of KRAS mutations is an independent negative prognosticator among Greek NSCLC patients and an independent response predictor to first line treatment. © 2019 International Institute of Anticancer Research. All rights reserved.
ER -